Skip to main content

Table 1 Age and gender stratified prevalence of anti-SARS-CoV-2 antibodies

From: Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!

  Age N Positive for SARS-CoV-2 antibodies – any test N (%) Positive for both anti-N-protein and anti-S-protein antibodies N (%) Crude prevalence (Any type of antibody) (%) Prevalence of both anti-N-protein and anti-S-protein antibodies (%)
Infants (N = 110) 0–3 months 68 25 (37) 19 (28) 36 27.2
4–9 months 42 15 (36) 11 (26.2)
Children (N = 284) 1–5 years old 141 44 (31) 34 (24.1) 33 25
6–17 years old 143 49 (34) 37 (26)
Women (N = 993) 18–44 years old 845 324 (38.3) 247 (29.2) 37 28.5
45–85 years old 148 47 (32) 36 (24.3)
Men (N = 105) 18–44 years old 63 21 (33) 16 (25.4) 37 28.6
45–78 years old 42 18 (43) 14 (33.3)
  1. N = number of participants; % percentage of participants (prevalence)